Polymorphisms in the α1A‐adrenoceptor gene do not modify the short‐ and long‐term efficacy of α1‐adrenoceptor antagonists in the treatment of benign prostatic hyperplasia

Publisher Website
Google Scholar
Abstract
OBJECTIVE: To determine whether a common single nucleotide polymorphism (SNP) in the ADRA1A gene encoding the α1A‐adrenoceptor modifies the short‐ and long‐term efficacy of α1‐adrenoceptor antagonists in the treatment of benign prostatic hyperplasia (BPH).PATIENTS AND METHODS: For 254 patients with BPH and/or lower urinary tract symptoms who received α1‐adrenergic antagonists for ≥ 3 months, the ADRA1A genotype at position 1475 of the coding region was determined. The patients’ short‐term response to treatment was determined for four outcome measures, i.e. the International Prostate Symptom Score (IPSS), the IPSS quality‐of‐life score, peak urinary flow rate, and obstruction grade, stratified by genotype. Eventual BPH‐related invasive therapy was used as the outcome for assessing the long‐term response to treatment. Genetic variants at positions 834, 896, 898 and 1831 were too rare to be considered in the analysis.RESULTS: There were no significant differences for the genotype strata in three of the four outcome measures. Patients with the CC genotype responded significantly better in quality‐of‐life perception than patients with the CT or TT genotype. There were also no significant differences in the risk of BPH‐related invasive therapy among the three genotypes.CONCLUSIONS: The 1475C→T SNP in the ADRA1A gene does not modify the short‐ and long‐term efficacy of α1‐adrenoceptor antagonists for treating BPH. There was a small effect on perceived quality of life but this was not reflected in other variables that measured the treatment response more directly.